DIA 48th Annual Meeting
Click here to go to the previous page
Practical Implementation of Knowledge Management
Track : Track 12: Pharmaceutical Quality
Program Code: 254
Date: Tuesday, June 26, 2012
Time: 1:30 PM to 3:00 PM  EST
 Georges France, Novartis Consumer Health S.A., Switzerland
Tara Gooen, FDA, United States
 Carol Bye, Pfizer Ltd, United Kingdom
 Stephan Roenninger, F. Hoffmann-La Roche Ltd., Switzerland
This session will discuss knowledge management (KM) during and after QbD development. We will discuss key data to be considered, IT tools support, practical experience and debate about regulatory expectations.

Learning Objectives:
Discuss the meaning of knowledge management during QbD development
Discuss how industry with experience of QbD submission manage the knowledge
Discuss the level of data which had to be considered in the Knowledge Management Illustration of IT tools to support knowledge management.

Handout Online